Fujifilm Medical to add IVD to portfolio

2020 08 17 23 11 0044 Fujifilm Rsna 2019 400

Fujifilm Medical Systems USA has announced that as of October 1, it will incorporate IVD into its portfolio by integrating Fujifilm Wako Diagnostics USA into the firm.

Fujifilm Wako Diagnostics has developed biomarkers that assess the risk of hepatocellular carcinoma in patients with chronic liver disease, as well as IVD reagents for disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes, according to Fujifilm Medical Systems.